A Randomized, Double-blind, Placebo-controlled, Single and Multiple Rising Dose Study to Explore the Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of SB26 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs SB-26 (Primary)
- Indications Pancreatitis
- Focus Adverse reactions
- Sponsors Samsung Bioepis
- 01 Oct 2019 Planned End Date changed from 20 Aug 2020 to 26 Mar 2020.
- 01 Oct 2019 Planned primary completion date changed from 8 Jul 2020 to 26 Mar 2020.
- 01 Oct 2019 Status changed from active, no longer recruiting to recruiting.